Summit Therapeutics (SMMT) Misses Q4 EPS by 21c
Tweet
Share
E-mail
Get Alerts SMMT Hot Sheet
Join SI Premium – FREE
Summit Therapeutics (NASDAQ: SMMT) reported Q4 EPS of (GBP0.29), GBP0.21 worse than the analyst estimate of (GBP0.08).
For earnings history and earnings-related data on Summit Therapeutics (SMMT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oppenheimer Starts Viatris (VTRS) at Outperform
- Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'
- Target (TGT) Declares $1.16 Quarterly Dividend; 2.9% Yield
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
